Redefining hormone sensitive disease in advanced prostate cancer

Advances in Urology

Volumn , Issue , 2012, Pages

  Hou, Xiaoyu ^a   Flaig, Thomas W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858221365     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/978531     Document Type: Review

References (48)

1. Jemal A., Bray F., Center M., Ferlay J., Ward E., Forman D., Global cancer statistics CA Cancer Journal for Clinicians 2011 61 2 69 90
2. Siegel R., Ward E., Brawley O., Jemal A., Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer Journal for Clinicians 2011 61 4 212 236
3. Schutz F. A., Oh W. K., Neoadjuvant and adjuvant therapies in prostate cancer Urologic Clinics of North America 2010 37 1 97 104
4. Machtens S., Schultheiss D., Kuczyk M., Truss M., Jonas U., The history of endocrine therapy of benign and malignant diseases of the prostate World Journal of Urology 2000 18 3 222 226
5. Huggins C., Hodges C. V., Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 Journal of Urology 2002 168 1 9 12
6. Labrie F., Adrenal androgens and intracrinology Seminars in Reproductive Medicine 2004 22 4 299 309 (Pubitemid 40030080)
7. Mohler J. L., Titus M. A., Wilson E. M., Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone Clinical Cancer Research 2011 17 18 5844 5849
8. Cai C., Balk S., Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy Endocrine-Related Cancer 2011 18 5 175 182
9. Serrate C., Loriot Y., De La Motte Rouge T., Gross-goupil M., Massard C., Escudier B., Bossi A., Fizazi K., Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer Annals of Oncology 2009 20 5 965
10. Granfors T., Modig H., Damber J. E., Tomic R., Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone Journal of Urology 2006 176 2 544 547 (Pubitemid 43927879)
11. Chrisp P., Goa K. L., Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions Drugs 1991 41 2 254 288 (Pubitemid 121000770)
12. Marberger M., Kaisary A. V., Shore N. D., Karlin G. S., Savulsky C., Mis R., Leuratti C., Germa J. R., Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a phase III, open-label, international multicenter study Clinical Therapeutics 2010 32 4 744 757
13. Kirby R. S., Fitzpatrick J. M., Clarke N., Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer BJU International 2009 104 11 1580 1584
14. Mahler C., Verhelst J., Denis L., Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer Clinical Pharmacokinetics 1998 34 5 405 417 (Pubitemid 28192908)
15. Shen H. C., Balk S. P., Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer Cancer Cell 2009 15 6 461 463
16. Choi B. K., Park C. H., Kim C. I., Comparison of ketoconazole- prednisolone combination therapy with prednisolone alone in patients with hormone refractory prostate cancer Korean Journal of Urology 2000 41 1183 1189
17. Tannock I., Gospodarowicz M., Meakin W., Panzarella T., Stewart L., Rider W., Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response Journal of Clinical Oncology 1989 7 5 590 597 (Pubitemid 19126794)
18. Flaig T. W., Glodé L. M., Management of the side effects of androgen deprivation therapy in men with prostate cancer Expert Opinion on Pharmacotherapy 2008 9 16 2829 2841
19. Klotz L., McNeill I., Fleshner N., A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma Journal of Urology 1999 161 1 169 172 (Pubitemid 29422313)
20. Nanda A., Chen M. H., Braccioforte M. H., Moran B. J., D'Amico A. V., Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction Journal of the American Medical Association 2009 302 8 866 873
21. Figg W. D., Woo S., Zhu W., Chen X., Ajiboye A. S., Steinberg S. M., Price D. K., Wright J. J., Parnes H. L., Arlen P. M., Gulley J. L., Dahut W. L., A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer Journal of Urology 2010 183 6 2219 2226
22. Antonarakis E. S., Eisenberger M. A., Expanding treatment options for metastatic prostate cancer The New England Journal of Medicine 2011 364 21 2055 2058
23. Deutsch E., Maggiorella L., Eschwege P., Bourhis J., Soria J. C., Abdulkarim B., Environmental, genetic, and molecular features of prostate cancer Lancet Oncology 2004 5 5 303 313 (Pubitemid 38541582)
24. Dutt S. S., Gao A. C., Molecular mechanisms of castration-resistant prostate cancer progression Future Oncology 2009 5 9 1403 1413
25. Harris W. P., Mostaghel E. A., Nelson P. S., Montgomery B., Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion Nature Clinical Practice Urology 2009 6 2 76 85
26. Loblaw D. A., Virgo K. S., Nam R., Somerfield M. R., Ben-Josef E., Mendelson D. S., Middleton R., Sharp S. A., Smith T. J., Talcott J., Taplin M., Vogelzang N. J., Wade J. L., Bennett C. L., Scher H. I., Initial hormonal management of Androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 Update of an American society of clinical oncology practice guideline Journal of Clinical Oncology 2007 25 12 1596 1605 (Pubitemid 46733088)
27. Tannock I. F., de Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Théodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer The New England Journal of Medicine 2004 351 15 1502 1512 (Pubitemid 39315317)
28. Petrylak D. P., Tangen C. M., Hussain M. H., Lara P. N., Jones J. A., Taplin M. E., Burch P. A., Berry D., Moinpour C., Kohli M., Benson M. C., Small E. J., Raghavan D., Crawford E. D., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer The New England Journal of Medicine 2004 351 15 1513 1520 (Pubitemid 39315318)
29. Vasaitis T. S., Bruno R. D., Njar V. C., CYP17 inhibitors for prostate cancer therapy Journal of Steroid Biochemistry and Molecular Biology 2010 125 1-2 23 31
30. Reid A. H., Attard G., Barrie E., de Bono J. S., CYP17 inhibition as a hormonal strategy for prostate cancer Nature Clinical Practice Urology 2008 5 11 610 620
31. Attard G., Reid A. H. M., A'Hern R., Parker C., Oommen N. B., Folkerd E., Messiou C., Molife L. R., Maier G., Thompson E., Olmos D., Sinha R., Lee G., Dowsett M., Kaye S. B., Dearnaley D., Kheoh T., Molina A., De Bono J. S., Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer Journal of Clinical Oncology 2009 27 23 3742 3748
32. Reid A. H., Attard G., Danila D., Oommen N. B., Olmos D., Fong P. C., Molife L. R., Hunt J., Messiou C., Parker C., Dearnaley D., Swennenhuis J. F., Terstappen L. W., Lee G., Kheoh T., Molina A., Ryan C. J., Small E., Scher H. I., de Bono J. S., Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate Journal of Clinical Oncology 2010 28 9 1489 1495
33. Dreicer R., Agus D. B., MacVicar G. R., Wang J., MacLean D., Stadler W. M., Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study Journal of Clinical Oncology 2010 28 15, supplement 3084 15s
34. Petrylak D. P., Current clinical trials in castrate-resistant prostate cancer Current Urology Reports 2008 12 3 3 179
35. Vasaitis T. S., Bruno R. D., Njar V. C., CYP17 inhibitors for prostate cancer therapy Journal of Steroid Biochemistry and Molecular Biology 2011 125 1-2 23 31
36. Molina A., Belldegrun A., Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling The Journal of Urology 2011 185 3 787 794
37. de Bono J. S., Logothetis C. J., Molina A., Abiraterone and increased survival in metastatic prostate cancer The New England Journal of Medicine 2011 364 21 1995 2005
38. Chen Y., Sawyers C. L., Scher H. I., Targeting the androgen receptor pathway in prostate cancer Current Opinion in Pharmacology 2008 8 4 440 448
39. Tran C., Ouk S., Clegg N. J., Chen Y., Watson P. A., Arora V., Wongvipat J., Smith-Jones P. M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C. D., Higano C. S., Beer T. M., Hung D. T., Scher H. I., Jung M. E., Sawyers C. L., Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009 324 5928 787 790
40. Scher H. I., Beer T. M., Higano C. S., Anand A., Rathkopf D., Shelkey J., Morris M. J., Danila D. C., Larson S., Humm J., Fleisher M., Sawyers C. L., Alumkal J., Sawyers C. L., Yu E. Y., Taplin M. E., Efstathiou E., Hung D., Hirmand M., Seely L., Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study The Lancet 2010 375 9724 1437 1446
41. Foster W. R., Car B. D., Shi H., Drug safety is a barrier to the discovery and development of new androgen receptor antagonists Prostate 2011 71 5 480 488
42. Massard C., Fizazi K., Targeting continued androgen receptor signaling in prostate cancer Clinical Cancer Research 2011 17 12 3876 3883
43. van Poppel H., Evaluation of degarelix in the management of prostate cancer Cancer Management and Research 2010 2 1 39 52
44. Pommerville P. J., de Boer J. G., GnRH antagonists in the treatment of advanced prostate cancer The Canadian Journal of Urology 2010 17 2 5063 5070
45. Klotz L., Boccon-Gibod L., Shore N. D., Andreou C., Persson B. E., Cantor P., Jensen J. K., Olesen T. K., Schrder F. H., The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU International 2008 102 11 1531 1538
46. Schrder F. H., Tombal B., Miller K., Boccon-Gibod L., Shore N. D., Crawford E. D., Moul J., Olesen T. K., Persson B. E., Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study BJU International 2010 106 2 182 187
47. Raddin R. S., Walko C. M., Whang Y. E., Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer Anti-Cancer Drugs 2011 22 3 299 302
48. Ryan C. J., Tindall D. J., Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically Journal of Clinical Oncology 2011 29 27 3651 3658